CJC-1295 (without DAC) combined with Ipamorelin is a dual-peptide research formulation pairing a modified growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue receptor (GHS-R) agonist. The two compounds engage complementary neuroendocrine signaling pathways that converge on somatotroph function, making this combination a widely utilized model in pituitary and neuroendocrine research. CJC-1295 without DAC (also referred to as Mod GRF 1-29) is a truncated, amino acid-substituted GHRH analog engineered for improved metabolic stability, while Ipamorelin is a pentapeptide ghrelin mimetic with high selectivity for the GHS-R1a receptor subtype.
In vitro work using pituitary cell models has shown that concurrent activation of both the GHRH and GHS-R pathways produces synergistic increases in cAMP accumulation and intracellular calcium mobilization, providing a useful experimental system for investigating receptor crosstalk and signal integration. The formulation has also been applied in studies examining dose-response relationships, temporal kinetics of combined receptor stimulation, and downstream transcriptional effects of coordinated pathway engagement in neuroendocrine cell systems.
Each component is independently verified for identity and purity by HPLC and mass spectrometric analysis, and the product is supplied with a certificate of analysis. This formulation is intended exclusively for in vitro laboratory research. It is not for human consumption, clinical application, or any purpose outside controlled laboratory use.
FDA Disclaimer
The information presented on this website has not been evaluated by the U.S. Food and Drug Administration. No content on this site, nor any product listed, is intended to diagnose, treat, cure, or prevent any disease or medical condition.
All products are supplied solely as laboratory research reagents and are not for human consumption. Ares Research does not supply products to patients and makes no representations regarding therapeutic or medical use.
Ares Research operates as a chemical supplier only. It is not a compounding pharmacy and does not function as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.
